Cargando…

Overcoming barriers to monitoring patients taking second-generation antipsychotics

INTRODUCTION: Patients taking second-generation antipsychotics (SGAs) are at increased risk of developing metabolic syndrome because of the side effect profiles of these medications. A medication use evaluation (MUE) was conducted and showed that baseline monitoring rates of metabolic parameters in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peña, Anita, DeJongh, Beth, Haas, Matthew, Harms, Michelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	College of Psychiatric & Neurologic Pharmacists 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007736/ https://www.ncbi.nlm.nih.gov/pubmed/29955545 http://dx.doi.org/10.9740/mhc.2018.03.049

Ejemplares similares

Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome
por: DeJongh, Beth M.
Publicado: (2021)

Comparison of clozapine monitoring and adverse event management in a psychiatrist-only and a clinical pharmacist-psychiatrist collaborative clinic
por: Maryan, Samantha, et al.
Publicado: (2019)

Arterial Stiffness in Patients Taking Second-generation Antipsychotics
por: Fındıklı, Ebru, et al.
Publicado: (2016)

Implementation and evaluation of depression screening in patients with recently diagnosed coronary artery disease
por: Mailloux, Lindsay M., et al.
Publicado: (2020)

Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone
por: Mailloux, Lindsay M., et al.
Publicado: (2021)

Case reports of interprofessional care for clients enrolled in a mental health court
por: DeJongh, Beth, et al.
Publicado: (2018)

Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
por: Fontaine, Jennifer, et al.
Publicado: (2022)

Metabolic consequences of second-generation antipsychotics in youth: appropriate monitoring and clinical management
por: Krill, Rebecca A, et al.
Publicado: (2014)

Toward the automated generation of genome-scale metabolic networks in the SEED
por: DeJongh, Matthew, et al.
Publicado: (2007)

Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
por: Divac, Nevena, et al.
Publicado: (2014)

A stopping criterion for iterative proton CT image reconstruction based on correlated noise properties
por: DeJongh, Ethan A., et al.
Publicado: (2023)

Enhancing Quality Measurement With Clinical Information: A Use Case of Body Mass Index Change Among Children Taking Second Generation Antipsychotics
por: Huo, Tianyao, et al.
Publicado: (2022)

Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
por: Caruso, Giuseppe, et al.
Publicado: (2020)

First-generation vs second-generation antipsychotic drugs: The ongoing saga
por: Gupta, Sumeet
Publicado: (2010)

Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs—Influence of Smoking Behavior and Inflammation on Pharmacokinetics
por: Moschny, Nicole, et al.
Publicado: (2021)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
por: Kumra, Sanjiv, et al.
Publicado: (2008)

Inhibition of mouse brown adipocyte differentiation by second-generation antipsychotics
por: Oh, Jee-Eun, et al.
Publicado: (2012)

Adherence and Continuation of Treatment with First- and Second-generation Antipsychotics in Schizophrenia
por: Warikoo, Nisha, et al.
Publicado: (2014)

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
por: McDonagh, Marian S., et al.
Publicado: (2020)

Combination treatment with second generation antipsychotics other than clozapine
por: Schmidt-Kraepelin, C.
Publicado: (2021)

Risk of Breast Cancer in Association with the Use of Second-generation Antipsychotics
por: Joo, Sung Woo, et al.
Publicado: (2022)

Factors Influencing the Use of Second-Generation Antipsychotics in Children with Psychosis
por: Ramachandran, Sujith, et al.
Publicado: (2016)

Teetering on the Edge: Second-Degree Atrioventricular Block Following Long-Acting Second-Generation Antipsychotic
por: Harrisingh, Kamahl, et al.
Publicado: (2023)

Dysphagia with second-generation antipsychotics: A case report and review of the literature
por: Crouse, Ericka L., et al.
Publicado: (2018)

Effectiveness of second generation antipsychotics: A systematic review of randomized trials
por: Johnsen, Erik, et al.
Publicado: (2008)

Blood lactate levels in patients receiving first- or second- generation antipsychotics
por: Glavina, Trpimir, et al.
Publicado: (2011)

Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated Review
por: Miller, Brian J., et al.
Publicado: (2011)

Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy
por: Jauhar, Sameer, et al.
Publicado: (2019)

Intentional Recreational Abuse of Quetiapine Compared to Other Second-generation Antipsychotics
por: Klein, Lauren, et al.
Publicado: (2017)

Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics
por: Rice, Jessie, et al.
Publicado: (2020)

Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
por: Grajales, Diana, et al.
Publicado: (2019)

Second-generation antipsychotic use during pregnancy and risk of congenital malformations
por: Ellfolk, Maria, et al.
Publicado: (2021)

Association of Lithium and Second-Generation Antipsychotics with Neurocognition in Youth with Bipolar Disorder
por: Jiang, Xinyue, et al.
Publicado: (2022)

Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?
por: Płaza, Olga, et al.
Publicado: (2022)

Neutropenia induced by several second-generation antipsychotics :A case report
por: Zarouf, H., et al.
Publicado: (2023)

Evaluation of oral antipsychotic supplementation of select second-generation long-acting injectable antipsychotics in an acute-care psychiatric setting
por: Alastanos, Jennifer N., et al.
Publicado: (2019)

Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis
por: Ansell, B. R. E., et al.
Publicado: (2015)

Tardive Dyskinesia in Older Persons Taking Antipsychotics
por: Citrome, Leslie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_56vtnc2upp09973u8otv3sopto